Hi Ahmed, are you referring to the pipeline mentioned by the company, below?
Positive results for DMX-200 would go some way to proving that Dimerix's Receptor HIT drug discovery platform is effective and likely to be effective again in these areas. I agree it would be good to out-licence DMX-200 and then work on the program below. It's a solid pipeline.
Hi Ahmed, are you referring to the pipeline mentioned by the...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |